@FierceMedDev: Boston Scientific: Watchman beats warfarin in follow-up. Article | Follow @FierceMedDev
@MarkHFierce: Nanostim's leadless pacer has had some success in early human trials. Future buyer St. Jude Medical must be pleased. Story | Follow @MarkHFierce
@DamianFierce: St. Jude: Independent analysis says Durata leads are safe, reliable. Report | Follow @DamianFierce
> Boston Scientific ($BSX) won a CE mark for Rhythmia, a 3-D mapping system used in electrophysiology procedures. Story
> Globus Medical ($GMED) has launched its Fortify I corpectomy spacer for spinal surgery. News
> Rosetta Genomics ($ROSG) has settled its spat with Sanra Laboratories, receiving a $625,000 payment. More
> Bacterin ($BONE) posted $8.6 million in first-quarter revenue, a 6% jump, and the company narrowed its losses by 3% to $1.2 million. Results
> Life Care Medical Devices has expanded into Europe, opening a Dublin outpost to base its continental operations. Item
> Critical Diagnostics is touting a new study establishing the ST2 biomarker, used in the company's Presage ST2 Assay, as the most potent predictor of heart failure rehospitalization. Release
Biotech News
@FierceBiotech: Novartis' Ilaris approved by FDA to treat active systemic juvenile idiopathic arthritis. Release | Follow @FierceBiotech
@JohnCFierce: Looks like Takeda management maybe in for more changes.The numbers are awful. Report | Follow @JohnCFierce
@RyanMFierce: My story on how industry legend Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups. Article | Follow @RyanMFierce
> Pain Therapeutics, Durect shares nosedive on haziness for Pfizer's Remoxy. Report
> Eli Lilly jettisons cancer contender after another Phase III failure. Story
> Biotech VC firm Frazier Healthcare closes in on $300M fund. More
> Deborah Dunsire exits as Takeda cuts CEO role in Millennium shakeup. News
Pharma News
@FiercePharma: WSJ: J&J's multibillion-$$ Risperdal settlement snags on breast side effects. $JNJ worried a/b civil suits. Article | Follow @FiercePharma
@EricPFierce: Pharma M&A way up in Q1 2013 compared to a year ago. Value up more than 500%. Feature | Follow @EricPFierce
> Motherhood at center of Merck gender bias suit. Article
> Amgen forges Chinese JV for Vectibix. Story